Catalent Competitors and Similar CompaniesClear all
Catalent's competitors and similar companies include Aldevron, Vetter Pharma, WuXi Biologics, Regeneron Pharmaceuticals, Gilead Sciences, Bristol Myers Squibb and Lonza.
 Catalent Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products. |  Aldevron Aldevron is a contract manufacturer providing biological products for research, clinical and diagnostic applications. |  Vetter Pharma Vetter Pharma-Fertigung is a company that specializes in aseptic filling for the pharmaceutical and biotech industries. |  WuXi Biologics WuXi Biologics (药明生物) is a company operating as an open-access technology platform for biologics drug development. |  Regeneron Pharmaceuticals Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines. |  Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines. |  Bristol Myers Squibb Bristol-Myers Squibb (BMS) is a company engaged in the discovery, development, licensing, manufacturing, marketing, and distribution of biopharmaceutical products. |  Lonza Lonza Group is a company that supplies active ingredients, chemical intermediates, and biotechnology solutions to the pharmaceutical and agrochemical industries. | |
Founding Date | Founding Date 2007 | Founding Date 1998 | Founding Date 1950 | Founding Date 2010 | Founding Date 1988 | Founding Date 1987 | Founding Date 1887 | Founding Date 1897 |
Type | Type Private | Type Subsidiary | Type Private | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||
Locations | Locations Somerset, US HQ Buenos Aires, AR Bruxelles, BE Charleroi, BE Charleroi, BE Charleroi, BE Indaiatuba, BR see more | Locations Fargo, US HQ Madison, US | Locations Ravensburg, DE HQ Rankweil, AT Shanghai, CN Langenargen, DE Ravensburg, DE Ravensburg, DE Ravensburg, DE see more | Locations Wuxi, CN HQ George Town, KY Wuppertal, DE Hong Kong, HK Dundalk, IE Cranbury, US King Of Prussia, US | Locations Tarrytown, US HQ Mississauga, CA Courbevoie, FR München, DE Bengaluru, IN Dublin, IE Limerick, IE see more | Locations Foster City, US HQ Buenos Aires, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more | Locations Princeton, US HQ Mulgrave, AU Pinewood, AU Wien, AT Braine L'alleud, BE Bruxelles, BE São Paulo, BR see more | Locations Basel, CH HQ Baulkham Hills, AU Antwerpen, BE Bornem, BE Verviers, BE Rio De Janeiro, BR Dorval, CA see more |
Employees | Employees 16,9005% decrease | Employees 830 | Employees 6,0858% increase | Employees 12,435 | Employees 15,1068% increase | Employees 18,0006% increase | Employees 34,100 | Employees 18,686 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 102.2 b | Valuation ($) 110.5 b | Valuation ($) 97.8 b | Valuation ($) N/A |
Financial | ||||||||
Revenue (est.) | Revenue (est.) $4.4b (FY, 2024) | Revenue (est.) $300m (Y, 2020) | Revenue (est.) €1b (FY, 2023) | Revenue (est.) ¥18.7b (FY, 2024) | Revenue (est.) $14.2b (FY, 2024) | Revenue (est.) $28.8b (FY, 2024) | Revenue (est.) $48.3b (FY, 2024) | Revenue (est.) CHF6.7b (FY, 2023) |
Cost of goods | Cost of goods $3.4b (FY, 2024) | Cost of goods N/A | Cost of goods €173m (FY, 2023) | Cost of goods ¥9.4b (FY, 2024) | Cost of goods $2b (FY, 2024) | Cost of goods $6.3b (FY, 2024) | Cost of goods $14b (FY, 2024) | Cost of goods CHF4.1b (FY, 2023) |
Gross profit | Gross profit $953m (FY, 2024) | Gross profit N/A | Gross profit €828.9m (FY, 2023) | Gross profit ¥9.5b (FY, 2024) | Gross profit $12.2b (FY, 2024) | Gross profit $22.5b (FY, 2024) | Gross profit $34.3b (FY, 2024) | Gross profit CHF2.6b (FY, 2023) |
Net income | Net income ($1b) (FY, 2024) | Net income N/A | Net income €74.9m (FY, 2023) | Net income ¥3.9b (FY, 2024) | Net income $4.4b (FY, 2024) | Net income $480m (FY, 2024) | Net income ($8.9b) (FY, 2024) | Net income CHF655m (FY, 2023) |
Operating ⚠ | ||||||||
Backlog | Backlog $2.5b (FY, 2023) | Backlog N/A | Backlog N/A | Backlog $18.5b (H1, 2022) | Backlog N/A | Backlog N/A | Backlog N/A | Backlog N/A |
Countries | Countries 80 (FY, 2023) | Countries N/A | Countries N/A | Countries N/A | Countries N/A | Countries 35 (FY, 2021) | Countries N/A | Countries 28 (FY, 2022) |
Customers | Customers 1.2 k (FY, 2023) | Customers N/A | Customers 125 (FY, 2022) | Customers N/A | Customers N/A | Customers N/A | Customers N/A | Customers N/A |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 7 (FY, 2019) | Phase I Trials Products (Oncology) 20 (FY, 2021) | Phase I Trials Products (Oncology) N/A |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 1 (FY, 2021) | Phase II Trials Products (Oncology) 15 (FY, 2021) | Phase II Trials Products (Oncology) N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 4 (FY, 2021) | Phase III Trials Products (Oncology) 7 (FY, 2021) | Phase III Trials Products (Oncology) N/A |
Products | Products 8 k (FY, 2023) | Products N/A | Products N/A | Products N/A | Products 11 (FY, 2022) | Products 21 (FY, 2021) | Products N/A | Products N/A |
Funding | ||||||||
Total funding raised | Total funding raised $ 650m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 53.9m | Total funding raised N/A | Total funding raised $ 15.5m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Aldevron
HQ
Fargo, US
Aldevron is a contract manufacturer providing biological products for research, clinical and diagnostic applications.
View companyVetter Pharma
HQ
Ravensburg, DE
Employees
6,085↑ 8% increase
Vetter Pharma-Fertigung is a company that specializes in aseptic filling for the pharmaceutical and biotech industries.
View companyWuXi Biologics
HQ
Wuxi, CN
Employees
12,435
WuXi Biologics (药明生物) is a company operating as an open-access technology platform for biologics drug development.
View companyRegeneron Pharmaceuticals
HQ
Tarrytown, US
Employees
15,106↑ 8% increase
Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.
View company